References

tiblj

Туберкулез и болезни легких

Tuberculosis and Lung Diseases

2075-12302542-1506

Медицинские знания и технологии

10.58838/2075-1230-2023-101-6-102-110

tiblj-1786

Research Article

ОБЗОР

REVIEW

Деламанид: анализ эффективности и безопасности

Delamanid: Safety and Efficacy Analysis

Можокина

Г. Н.

Mozhokina

G. N.

Можокина Галина Николаевна, д.м.н., ведущий научный сотрудник научной лаборатории иммунопатологии и иммунодиагностики туберкулезной инфекции

127473, г. Москва, ул. Достоевского, д. 4

Тел.: +7 (926) 653-45-16

Galina N. Mozhokina, Doctor of Medical Sciences, Leading Researcher of Research Laboratory of Immunopathology and Immunodiagnostics of Tuberculosis Infection

4 Dostoevsky St., Moscow, 127473

Phone: +7 (926) 653-45-16

mojokina@mail.ru

Самойлова

А. Г.

Samoylova

A. G.

Самойлова Анастасия Геннадьевна, д.м.н., первый заместитель директора по научной работе

127473, г. Москва, ул. Достоевского, д. 4

Тел.: +7 (903) 207-61-78

Anastasiya G. Samoylova, Doctor of Medical Sciences, First Deputy Director for Research

4 Dostoevsky St., Moscow, 127473

Phone: +7 (903) 207-61-78

a.samoilova.nmrc@mail.ru

https://orcid.org/0000-0002-0637-7955

Васильева

И. А.

Vasilyeva

I. A.

Васильева Ирина Анатольевна, д.м.н., профессор, директор, заведующая кафедрой фтизиатрии ФГАОУ ВО «РНИМУ им. Н. И. Пирогова» МЗ РФ

127473, г. Москва, ул. Достоевского, д. 4

Irina A. Vasilyeva, Doctor of Medical Sciences, Professor, Director, Head of Phthisiology Department, Pirogov Russian National Research Medical University, Russian Ministry of Health

4 Dostoevsky St., Moscow, 127473

vasil39@list.ru

Абрамченко

А. В.

Abramchenko

A. V.

Абрамченко Анна Валентиновна, младший научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, г. Москва, ул. Достоевского, д. 4

Тел.: +7 (917) 544-90-18

Anna V. Abramchenko, Junior Researcher of Research Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

4 Dostoevsky St., Moscow, 127473

Phone: +7 (917) 544-90-18

av.abramchenko@mail.ru

ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of HealthRussian Federation

2023

25122023

1016102110

2023

Можокина Г.Н., Самойлова А.Г., Васильева И.А., Абрамченко А.В.

Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Abramchenko A.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.tibl-journal.com/jour/article/view/1786

В обзоре представлен анализ 50 публикаций, в которых рассмотрено лечение туберкулеза с множественной лекарственной устойчивостью с включением нового препарата деламанид. Деламанид обладает двойным бактерицидным действием не только в отношении активных, но и дормантных микобактерий туберкулеза. Представлены результаты клинических исследований эффективности и безопасности применения деламанида в составе комплексной химиотерапии. Показаны перспективы расширения использования деламанида для лечения взрослых и детей.

The review presents the analysis of 50 publications describing treatment of multiple drug resistant tuberculosis with regimens containing the new drug of delamanid. Delamanid possesses a dual bactericidal effect not only against active but also dormant Mycobacterium tuberculosis. The results of clinical studies on the efficacy and safety of delamanid within comprehensive chemotherapy are presented. The review demonstrates prospects for expanding the use of delamanid for treatment of adults and children.

туберкулезмножественная лекарственная устойчивостьделаманидпротивотуберкулезная активностьнежелательные явления

tuberculosismultiple drug resistancedelamanidanti-tuberculosis activityadverse events

References1

Зимина В. Н., Викторова И. Б. Деламанид – новый противотуберкулезный препарат: применение, ограничения, перспективы // Туберкулёз и болезни лёгких. – 2021. – Т. 99, № 2. – С. 58-66.

Zimina V.N., Viktorova I.B. Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 2, pp. 58-66. (In Russ.)

Клинические рекомендации «Туберкулез у взрослых», 2020, 79 с. http://cr.minzdrav/-gov.ru/recomend/16

Klinicheskie rekomendatsii Tuberkulez u vzroslykh. [Clinical guidelines on tuberculosis in adults]. 2020, 79 p. http://cr.minzdrav/-gov.ru/recomend/16

Марьяндышев А.О., Лорсанов С.М., Хайдарханова З.Б., Хункарсултанов С.Б., Перхин Д.В., Свешникова О.М., Гайда А.И., Привольнев В.В. Результаты применения деламанида в лечении туберкулеза с множественной и широкой лекарственной устойчивостью возбудителя в Российской Федерации // Туберкулез и болезни легких. –2019. – Т.97,№11. –С.67-68.

Maryandyshev A.O., Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B., Perkhin D.V., Sveshnikova O.M., Gayda A.I., Privolnev V.V. Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 67-68. (In Russ.)

Можокина Г. Н., Самойлова А. Г., Васильева И. А., Русских А. Е. Препараты для краткосрочной химиотерапии лекарственно-устойчивого туберкулеза и их влияние на организм человека // Туберкулёз и болезни лёгких. – 2022. – Т. 100, № 8. – С. 54-64.

Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Russkikh A.E. Medications for short-course chemotherapy of drug resistant tuberculosis and their effect on the host. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 8, pp. 54-64. (In Russ.)

Русских А. Е., Кутузова Д. М., Ловачева О. В., Самойлова А. Г., Васильева И. А. Краткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективы. Туберкулёз и болезни лёгких. — 2020. - Т. 98, № 12.—С. 57-66

Russkikh A.E., Kutuzova D.M., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A. Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 12, pp. 57-66. (In Russ.)

Auchynka V., Kumar A.M.V., Hurevich H., Sereda Y., Solodovnikova V., Katovich D., Setkina S., Yedilbayev A., Skrahin A., Skrahina A. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18 // Monaldi Arch Chest Dis. – 2021. – Vol. 91,№ 1S.

Chang K. C., Sotgiu, G. Treatment options for MDR-and XDRTB // Anti Infect. Lung ERS Monogr. –2017. – №75. – Р.232.

Chen X., Hashizume H., Tomishige T., Nakamura I., Matsuba M., Fujiwara M., Kitamoto R., Hanaki E., Ohba Y., Matsumoto M. Delamanid kills dormant mycobacteria in vitro and in a guinea pig model of tuberculosis //Antimicrob Agents Chemother. – 2017, – № 61. – Р.02402-16.

D'Ambrosio L., Centis R., Tiberi S., Tadolini M., Dalcolmo M., Rendon A., Esposito S., Migliori GB. Delamanid and bedaquiline to treat multi-drug-resistant and extensively drug-resistant tuberculosis in children: a systematic review // J Thorac Dis. – 2017. –№ 9. – Р.2093-2101.

Das M., Dalal A., Laxmeshwar C., Ravi S., Mamnoon F., Meneguim A.C., et al. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India // Clin Infect Dis. – 2021. – Vol.73, №9. – Р.3496–e3504.

Deltyba EPAR Product Information, Annex I summary of product characteristics. European Medicines Agency, Committee for Medicinal Products for Human Use; 2014 Available at: https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product-informatio n_en.pdf [Accessed Oct 03, 2023]

Deltyba, INN-Delamanid—European Medicines Agency—Europa. Available online: https://www.ema.europa.eu/en/edicines/human/EPAR/deltyba 2014 Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba [Accessed Oct 01, 2023]

Deltyba, INN-Delamanid—European Medicines Agency—Europa. Available online: https://www.ema.europa.eu/en/ edicines/human/EPAR/deltyba 2014 Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba [Accessed Oct 01, 2023]

Diacon A.H., Dawson R., Hanekom M., Narunsky K., Venter A., Hittel N., Geiter L.J., Wells C.D., Paccaly A.J., Donald P.R. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients // Int J Tuberc Lung Dis. – 2011. – Vol.15, №7. – Р.949-54.

European Medicines Agency. 2021. Deltyba summary of product characteristics 2021. European Medicines Agency, Amsterdam, The Netherlands. Available at: https://www.ema.europa.eu/en/documents/product-information/deltybaepar-product-information_en.pdf. [Accessed Oct 03, 2023]

Ferlazzo G., Mohr E., Laxmeshwar C., Hewison C., Hughes J., Jonckheere S., Khachatryan N., De Avezedo V., Egazaryan L., Shroufi A., Kalon S., Cox H., Furin J., Isaakidis P. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study // Lancet Infect Dis. – 2018. – Vol.18, № 5. – Р.536-544.

Fujiwara M., Kawasaki M., Hariguchi N., Liu Y., Matsumoto M. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis // Tuberculosis (Edinb). –2018 – №108. –Р.186 –194.

Garcia-Prats A.J., Frias M., van der Laan L., De Leon A., Gler M.T., Schaaf H.S., Hesseling A.C., Malikaarjun S., Hafkin J. Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial // Antimicrob Agents Chemother. – 2022. – Vol.66, №5. – Р.0214421.

Gler M.T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J.L., Vargas-Vasquez D.E., Gao M., Awad M., Park S.K., Shim T.S., Suh G.Y., Danilovits M., Ogata H., Kurve A., Chang J., Suzuki K., Tupasi T., Koh W.J., Seaworth B., Geiter L.J., Wells C.D. Delamanid for multidrug-resistant pulmonary tuberculosis // N Engl J Med. – 2012. – Vol.366, № 23. – Р. 2151-60.

Hafkin J, Hittel N, Martin A, Gupta R. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis // Eur Respir J. 2019. – Vol.53, № 1. –Р.1801154.

Hatami H., Sotgiu G., Bostanghadiri N., Dolat Abadi S.S., Mesgarpour B., Goudarzi H., et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis // J Bras Pneumol. – 2022. – Vol.48, № 2.

Hewison C., Khan U., Bastard M., Lachenal N., Coutisson S., Osso E., et al. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort // Clin Infect . – 2022. – Vol.75,№6. – Р.1006-1013.

Igarashi M. Development of new antituberculosis drugs from natural products // Biosci. Biotechnol. Biochem. – 2017. – № 81. – Р. 32–37.

Kadura S., King N., Nakhoul M., Zhu H., Theron G., Köser C.U., Farhat M. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid // J Antimicrob Chemother. – 2020. – Vol.75, №8. – Р.2031-2043.

Kang H., Jo K.W., Jeon D., Yim J.J., Shim T.S. Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea // Respir Med. – 2020. – №167. – Р.105956.

Kim C.T, Kim T.O, Shin HJ, Ko Y.C., Choe Y.H., Kim H-R, Kwon Y.-S. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multi-center cohort study in Korea // Eur Respir J. – 2018. – №51. –Р.1702467

Kuksa L., Barkane L., Hittel N., Gupta R. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens // Eur Respir J. – 2017. – Vol.50,№ 5. – Р.1701105.

Kwon Y.S., Jeon D., Kang H., Yim J.J., Shim T.S. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea // Eur Respir J. – 2021. – Vol.57, №3

Lewis J.M., Sloan D.J. The role of delamanid in the treatment of drug-resistant tuberculosis // Ther Clin Risk Manag. – 2015. – №11. – Р. 79-91.

Liu Y., Matsumoto M., Ishida H., Ohguro K., Yoshitake M., Gupta R., Geiter L., Hafkin J. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB) // Tuberculosis (Edinb). – 2018. – №111. –Р.20-30.

Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., Shimokawa Y., Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice // PLoS Med. – 2006. – Vol.3, № 11. – Р.466.

Mohr E., Hughes J., Reuter A., Trivino Duran L., Ferlazzo G., Daniels J., et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa // Eur Respir J. – 2018. – Vol.51, № 6. – Р.1800017.

Mok J., Kang, H., Koh, W.-J., Jhun, B. W., Yim, J.-J., Kwak, N., Lee T., Kang B., Jeon D. Final treatment outcomes of delamanid-containing regimens in patients with MDR- /XDR-TB in South Korea // Eur. Respir. J. – 2019. – №54. – Р.1900811.

Nasiri M.J., Zangiabadian M., Arabpour E., Amini S., Khalili F., Centis R., et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis // Int J Infect Dis. – 2022. – 124 Suppl 1(Suppl 1). –Р.S90-S103.

Nguyen T.V.A., Anthony R.M., Cao T.T.H., Bañuls A.L., Nguyen V.A.T., Vu D.H., et al. Delamanid Resistance: Update and Clinical Management // Clin Infect Dis. – 2020. – Vol.71, № 12.Р. – 3252-3259.

Olayanju, O., Esmail, A., Limberis, J., and Dheda, K. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drugresistant tuberculosis // Eur. Respir. J. – 2020. – №55. –Р.1901181.

Pontali E., Sotgiu G., Tiberi S., Tadolini M., Visca D., D'Ambrosio L., Centis R., Spanevello A., Migliori G. B. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review // European Respiratory Journal. – 2018. – № 52. – Р.1800934;

Reichmuth M.L., Hömke R., Zürcher K., Sander P., Avihingsanon A. Collantes J., et al.иNatural polymorphisms in Mycobacterium tuberculosis conferring resistance to delamanid in drugnaive patients // Antimicrob Agents Chemother. – 2020, № 64. – Р.00513-20.

Ryan N. J., Lo J. H. Delamanid: first global approval // Drugs. – 2014. – №74. – Р. 1041–1045.

Sasabe H., Shimokawa Y., Shibata M., Hashizume K., Hamasako Y., Ohzone Y., Kashiyama E., Umehara K. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters // Antimicrob Agents Chemother. – 2016. Vol.60, № 6. – Р.3497-508.

Sasahara K., Shimokawa Y., Hirao Y., Koyama N., Kitano K., Shibata M., et al. Pharmacokinetics and metabolism of delamanid, a novel antituberculosis drug, in animals and humans: importance of albumin metabolism in vivo // Drug Metab. Dispos. – 2015. – №43. – Р.1267–1276.

Shibata M., Shimokawa Y., Sasahara K., Yoda N., Sasabe H., Suzuki M., Umehara, K. Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis // Biopharm. Drug Dispos. – 2017. – №38. – Р.301–312.

Shimokawa Y., Sasahara K., Koyama N., Kitano K., Shibata M., Yoda N., Umehara K. Мetabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma // Drug Metabolism and Disposition. – 2015. – Vol. 43, № 8. – Р. 1277-1283.

Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T., Cirule A., et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. – Eur Respir J. – 2013. – Vol.41, № 6. – Р.1393-400.

Szumowski J.D., Lynch J.B. Profile of delamanid for the treatment of multidrug-resistant tuberculosis // Drug Des Devel Ther. – 2015. – № 9. – Р.677-82. 45. Tadolini M., Lingtsang R.D., Tiberi S., Enwerem M., D’Ambrosio L., Sadutshang T. D., Centis R., Migliori G.B. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline // Eur Respir J. – 2016. – № 48. – Р. 935–938.

Tesema E., Wares F., Bedru A., Negeri C., Molla Y., Gemechu D., et al. Experiences of introducing new drugs for drug-resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017–2019 // Public Health Action . – 2021. – № 11. – Р.50–52.

Vilchèze C. Mycobacterial cell wall: a source of successful targets for old and new drugs // Appl. Sci. – 2020. – Vol.10. – Р.2278.

Von Groote-Bidlingmaier F., Patientia R., Sanchez E., Balanag V. Jr., Ticona E., Segura P., et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial // Lancet Respir Med. – 2019. – Vol.7, № 3. – Р.249-259.

WHO Consolidated guidelines on tuberculosis, Module 4: treatment ‒ drug-resistant tuberculosis treatment [Electronic resource]. Available at: https://www.who.int/publications/i/item/9789240007048 [Accessed Oct 03, 2023]

Zhang Q., Liu Y., Tang S., Sha W., Xiao H. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China // Cell Biochem Biophys. – 2013. –Vol.67, №3. – Р.957-63.

The authors declare that there are no conflicts of interest present.